COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

BACKGROUND: Monoclonal antibody (mAb) treatment for COVID-19 is associated with improved clinical outcomes. However, there is limited information regarding the impact of treatment on symptoms and the prevalence of post-COVID Conditions (PCC). Understanding of the association between time to mAb infu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vawter, Natalie L., Godino, Job G., Lewis, Sydney V., Northrup, Adam W., Samaniego, Jane C., Poblete, Jacqueline Y., Guereca, Jesus A., Sharp, Sydney P., Matthews, Eva, Crespo, Noe C., Lucatero, Pauline G., Vidaurrazaga, Monica M., Ramers, Christian B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944776/
https://www.ncbi.nlm.nih.gov/pubmed/36814187
http://dx.doi.org/10.1186/s12879-023-08057-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944776/
https://www.ncbi.nlm.nih.gov/pubmed/36814187
http://dx.doi.org/10.1186/s12879-023-08057-7

Ejemplares similares